{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011079","form_type":"8-K","ticker":null,"cik":"0001173281","company_name":"NeuBase Therapeutics, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.142677+00:00","generated_at":"2026-06-14T00:53:22.224069+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuBase Therapeutics to effect 1-for-20 reverse stock split to regain Nasdaq compliance","bullets":["Reverse stock split at 1-for-20 effective 5:00 p.m. ET June 14, 2023; trading begins June 15 under symbol NBSE.","Split intended to regain $1.00 minimum bid price for continued Nasdaq listing.","Outstanding shares reduced from ~33.8 million to ~1.7 million.","No fractional shares; cash paid in lieu based on June 13 closing price.","Board approved ratio June 9, 2023; stockholder authorization received Sept 8, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011079","json":"https://secwatch.observer/filing/0001558370-23-011079.json","markdown":"https://secwatch.observer/filing/0001558370-23-011079.md","text":"https://secwatch.observer/filing/0001558370-23-011079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173281/000155837023011079/0001558370-23-011079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173281/000155837023011079/nbse-20230614x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:53:22.224069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"192c2d6cdce6f1965bb9a14f04535990350c5847","claim":"NeuBase Therapeutics, Inc.: Filed Certificate of Amendment to effect 1-for-20 reverse stock split (effective 2023-06-14).","evidence_excerpt":"On June 14, 2023, NeuBase Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company’s shares of common stock (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000155837023011079/0001558370-23-011079-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}